A randomized discontinuation trial to determine the clinical benefit of continuation of sorafenib following disease progression in patients with advanced renal cell carcinoma.

Trial Profile

A randomized discontinuation trial to determine the clinical benefit of continuation of sorafenib following disease progression in patients with advanced renal cell carcinoma.

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 08 Jan 2015

At a glance

  • Drugs Gemcitabine; Interferon; Sorafenib
  • Indications Renal cancer
  • Focus Therapeutic Use
  • Acronyms PROGRESS
  • Sponsors Bayer
  • Most Recent Events

    • 01 Apr 2009 Planned end date added as 1 Nov 2006 as reported by ClinicalTrisl.gov.
    • 14 Jul 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top